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STRUCTURED SUMMARY 
Background 
Biological therapy is currently widely used to treat inflammatory bowel disease (IBD). Infliximab, 
adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF 
monoclonal antibodies are increasingly used. Anti-TNF therapies are most widely used and their 
adverse effects are best characterised, which may cause significant morbidity and mortality in a 
small proportion of exposed patients. Gastroenterologists need to understand the mechanism for 
these effects, recognise these swiftly and manage such events appropriately.  
Aim 
This review aims to cover the range of potential adverse reactions as a result of biologic therapy 
and specifically management of these events. 
Methods 
A Medline and Pubmed search was undertaken. Search terms included were “anti-TNF”, “infliximab” 
or “adalimumab” or “golimumab” combined with the keywords “ulcerative colitis” or “Crohn’s disease” 
or “inflammatory bowel disease” and then narrowed to articles containing the keywords 
“complications”, “side effects” or “adverse events” or “safety profile”. International guidelines were 
also reviewed where relevant.  
Results 
Adverse events discussed in this review include infusion reactions, blood disorders and infections 
(including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological 
disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological, 
and those linked to viral disease are discussed.  
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Conclusions 
Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential 
adverse events in a small proportion of patients. Research advances are improving understanding, 
recognition and management of these adverse events. 
INTRODUCTION 
The use of biologics is currently approved for moderate-to-severe Crohn’s disease (CD) and 
moderate to severe ulcerative colitis (UC)1-9. Infliximab, adalimumab and golimumab are antibodies 
to tumour necrosis factor-α (TNFα). These drugs work on a common pathway of blocking TNFα, a 
pro-inflammatory cytokine closely linked to acute phase reaction and systemic inflammation, thereby 
reducing the degree of damage to tissues. These have been developed using different techniques 
therefore conferring different degrees of immunogenicity. [Infliximab (human-chimeric), adalimumab 
(fully human), golimumab (fully human), certolizumab (recombinant pegylated humanised Fab’ 
fragment)]. 
These medications have transformed medical treatment options for inflammatory bowel disease 
(IBD) in recent years and are prescribed in increasing numbers. As there are less golimumab 
exposed patients than the other two anti-TNF monoclonal antibodies, less adverse effects have 
been reported but generally most adverse effects are class effects. Clinicians need to be aware of 
& recognise adverse events (AE/AEs) that may result from the use of these drugs and also have 
clear management strategies in different scenarios. This comprehensive review summarises a 
range of possible AEs providing evidence based guidance where available and pragmatic guidance 
for areas where evidence is lacking. 
 
 
5 
 
AIMS AND METHODS: 
A MEDLINE and PUBMED search was undertaken by (U.S, C.L) for articles pertaining to adverse 
effects of anti-TNF therapy in IBD. After an initial title screen, all relevant articles were examined in 
full. The main aim of the review is to focus on management of adverse events caused by anti-TNF 
therapy. For clarity, these AEs are discussed in categories as per systems, alongside recommended 
course of action including any further investigations or management. Where relevant, this 
manuscript also refers to international guidelines. 
Non-infectious complications and management strategies 
Hypersensitivity reactions 
Hypersensitivity reactions vary widely in presentation, ranging from acute infusion reactions                
to delayed hypersensitivity.  
o Type I acute hypersensitivity reactions (IgE mediated) present as anaphylaxis 
o Type II are cytotoxic; complement-mediated  
o Type III are immune-complex related presenting as serum sickness   
o Type IV are cell-mediated delayed hypersensitivity; mediated by T lymphocytes 
Acute infusion reactions (IR) are defined as those which occur during or within 24 hours of the 
infusion. The symptoms vary and reactions can range from mild (flushing, dizziness, headache, 
itching, rash) to severe (anaphylactic-like)2. Acute infusion reactions are relatively common, 
estimated to occur in up to 5% of infusions, with less than 1% of all infusions resulting in a severe 
reaction3.  
Patients with antibodies to infliximab are at an increased risk of infusion reactions4 and case reports 
suggest hypersensitivity to adalimumab are also associated with adalimumab antibodies5. A review 
by the Food and Drug Administration (FDA) reported that injection site reactions were more common 
with adalimumab6 with higher reporting odds ratio(ROR) in the 20-29y age group (ROR=16.18). The 
ROR was seen to reduce with increasing age6. Injection site reactions to golimumab in the PURSUIT 
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study were low at 3.4% with no reported anaphylaxis or delayed hypersensitivity to 6 weeks7. 
Delayed reactions (24 hours to 14 days) presenting with arthralgia, myalgia, fever, fatigue and rash 
are much rarer (<1%)3. The pathophysiology of immunologic features are not completely 
understood8.  
Management  
The management of IRs is generally similar regardless of which agent has caused it. Typically, 
symptoms improve substantially or resolve completely after infusion rate adjustments and treatment 
with paracetamol, antihistamines or corticosteroids are provided. Evidence to support the use of 
premedication with corticosteroids or antihistamines is limited, with patients still experiencing 
infusion reactions despite pre-medication9 and therefore should be considered on an individual 
basis. Injection site pain due to adalimumab can be reduced by using low volume formulations which 
are free from citrate buffers, with no change in efficacy10.  
In severe acute reactions, it is recommended that infusion is stopped and focus should be on 
maintaining airway, circulation as per standard anaphylaxis guidelines11. (Table 1) Delayed infusion 
reactions are typically managed by antihistamines, paracetamol and corticosteroids. A systematic 
review looked at management of infusion reactions and presented useful algorithms to manage mild, 
moderate and severe reactions12. These algorithms are simple, and a pragmatic tool to use for the 
vast majority of reactions seen in clinical practice12. After a hypersensitivity reaction, it is pragmatic 
to obtain therapeutic drug levels and anti-drug antibody levels.   
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Anti – TNF: Anti-Tumour Necrosis Factor; ALS: Advanced Life Support  
 
Table 1- Hypersensitivity reactions to anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Type 1 Hypersensitivity  
This is more common when antibody 
titres are high. Incidence is higher 
during re-introduction of drugs 
 • Clinical diagnosis 
• Serum mast cell tryptase 
• Detection of antibodies on serum analysis 
where available 
1. Mild reactions: Slow infusion rates 
2. Consider hydrocortisone injections as a pre-
administration medication 
3. Anaphylaxis reactions: Treat as per ALS pathway 
with adrenaline, steroids and anti-histamines 
Type 2 Complement Mediated  
Non-specific symptoms 
 • Detection of antibodies on serum analysis 
where available 
1. Symptomatic treatment 
2. Consider stopping treatment 
Type 3 Immune-Complex Mediated 
Serum sickness 
 • Difficult to detect on assays, immune 
complexes known to adhere to membranes 
1. Symptomatic treatment 
2. Consider stopping the drug and switch if antibodies 
are confirmed 
Type 4 T-Cell Mediated 
Delayed hypersensitivity reaction (after 
24 hours up to 14 days post-infusion). 
 • Clinical diagnosis 
 
1. Symptomatic management 
2. Consider stopping drug 
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Haematological effects 
Leucopoenia 
Neutropenia has been reported in anti-TNFα treatment-exposed patients, with up to 20% of patients 
developing neutropenia on at least one occasion13. TNFα up-regulates other pro-inflammatory 
cytokines, including interleukin-1 (IL-1), IL-6, IL-8, and granulocyte–macrophage colony-stimulating 
factor, involved in the differentiation and maturation of haematopoietic progenitor cells14. TNFα 
blockade could mediate bone marrow failure by inhibiting stem cell differentiation15. However, the 
reduction in neutrophil count following TNFα inhibitor therapy is not seen for other cells from the 
same lineage (myeloid progenitor cell), specifically basophils, eosinophils and monocytes. The risk 
of neutropenia is significantly higher in patients with a low baseline neutrophil count or a previous 
history of neutropenia13,16.   
Thrombocytopenia 
Isolated thrombocytopenia following the use of anti-TNF drugs17,18 has been reported. There are 
multiple hypotheses as to the possible aetiology, including autoimmune platelet destruction 
secondary to antiplatelet antibodies, immune complexes triggering the complement cascade, 
another unknown autoimmune mechanism, or idiosyncratic reaction18.  
Anaemia 
Anaemia is considered a marker of active disease in IBD and therefore clinicians need to first 
consider this as an aetiology. The incidence and prevalence of anaemia was approximately 19% 
and 28% respectively, in a recent population based cohort study. Crohn’s with stricturing disease 
and long-standing UC were recognised as risk factors19. One study showed only marginal 
improvement in anaemia after treatment with anti-TNF therapy suggesting that disease activity in 
itself has a major role to play20.  
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In this section, anaemia directly attributable to biologics is discussed, which is rare. There are 
sporadic case reports of aplastic anaemia with infliximab, more commonly in patients with 
rheumatoid arthritis than IBD21. A single case of infliximab induced autoimmune haemolytic anaemia 
(in a patient found to be anti-nuclear antibody (ANA) positive 1:40) has also been reported22.  
Management of haematological effects 
All patients starting anti-TNF therapy should have a baseline complete blood count with repeat 
testing every three to six months. At the onset of neutropenia, the anti-TNF should be withheld if the 
neutrophil count is deemed too low by the clinician. The patient should be left drug-free until 
neutrophil counts recover & anti-TNF therapy restarted when deemed clinically safe. Neutropenia 
can occur in patients managed with combination therapy with an anti-metabolite and this should be 
borne in mind and should be discontinued first.  A neutrophil count less than 1000/mm3 should raise 
concern and <500/mm3 should lead to discontinuation of incriminating drugs and close monitoring. 
Rare anti-TNF induced systemic lupus erythematosus should be excluded and sargramostim is 
rarely necessary after drug discontinuation. 
Thrombocytopenia can be managed by drug cessation, corticosteroid therapy or rescue therapy 
with intravenous immunoglobulin (IVIG). Thrombocytopenia has been reported to be prolonged after 
cessation of therapy. In severe cases this could persist for up to 6 months and also preclude 
exposure to any further anti-TNF agents18. This is likely to be a class effect and re-challenge with 
same class could be risky and therefore discouraged17. In severe cases, specialist haematology 
input is suggested. 
Anaemia in IBD is more commonly seen due to ongoing disease activity. Clinicians should first 
consider assessment for disease and strategies to control and manage anaemia secondary to 
disease as per guidelines. As anaemia related only to therapy is rare, there is no specific guidance 
in current literature regarding future therapy with anti-TNF. Cessation of therapy would depend on 
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careful physician-patient discussion taking into account the severity of anaemia and alternative 
treatment strategies. Involving haematologist in refractory cases would be prudent. (Table 2)  
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G-CSF- Granulocyte-Colony Stimulating Factor 
 
Table 2- Haematological complications with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Leucopenia 
Neutropenia 
 • Blood count monitoring 
 
1. If < safety threshold: stop drug, monitor blood 
count 
2. Restart drug when counts are within normal 
range 
3. Monitor 
4. Consider G-CSF 
Thrombocytopenia  • Blood count monitoring 
• Establish temporal relationship to drug 
• Secondary cases of low platelets to be excluded 
including concomitant drug therapy 
1. If < safety threshold: stop drug, monitor platelet 
count 
2. Consider IV immunoglobulins & steroids 
3. Consider switching to different class of biologic 
Anaemia 
Drug related anaemia is rare but 
aplastic anaemia can be serious 
 • Blood count monitoring 
• Bone marrow aspiration in refractory cases 
1. If aplastic anemia: withdraw and stop drug 
2. Refractory cases warrant specialist hematology 
assessment 
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Dermatological effects 
In addition to skin malignancies anti-TNF therapy can cause a wide range of dermatological 
conditions. Most notably they include local skin irritation or reaction, increased skin infection rates, 
psoriasis, eczema, acne, and alopecia. Other rare dermatological complications include erythema 
nodosum23, granuloma annulare and interstitial granulomatous dermatitis. Although some of the 
above complications are also seen as extra-intestinal manifestations of disease, temporal 
association with biologic therapy should help differentiate disease related complications from drug 
related complications.  
Psoriasis and psoriasiform reactions can occur directly as a result of anti-TNFα therapy, which 
interestingly is used by dermatologists to treat severe cases of psoriasis. Psoriasis is a relatively 
common side effect of anti-TNFα therapy, with 1.5-5% of patients developing this manifestation24. It 
is seen most commonly in females, typically 2-6 months following initiation of therapy25. A nation-
wide cohort study reported incidence rates of anti-TNF induced psoriasis in IBD at 0.5% per patient-
year26. A more recent study shows a much higher incidence at 10.5%27, but psoriasiform lesions are 
more common than psoriasis and have distinctive features. According to current evidence, females, 
smokers and patients with fistulising disease appear to be at risk27. In addition to anti-TNFα induced 
psoriasis, psoriasiform and drug-induced psoriasiform lesions have been well recognised. 
Psoriasiform drug reactions can be distinguished histologically from psoriasis and resolve swiftly on 
cessation of drug therapy. Re-challenge results in recurrence of the lesions. The psoriasiform 
lesions could be secondary to infections and resolve on its treatment, though the infective origin of 
these are not always clear nor are their implications25.  
The exact mechanism triggering de novo psoriasis is unclear, although it has been postulated to be 
secondary to increased cutaneous expression of interferon alpha (IFNα). IFNα is released from 
dendritic cells to recruit T cells and pro-inflammatory cytokines IL-12 and IL-23. TNFα would 
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normally block IFNα expression and so anti-TNFα results in up regulation of IFNα24. Higher levels 
of IFN are seen in anti-TNFα induced psoriasis than idiopathic psoriasis25.   
Management 
Management of psoriasis due to anti-TNFα depends on severity of symptoms. Milder cases of 
psoriasis can be treated clinically with topical therapy without cessation of anti-TNF, however more 
severe cases may require anti-TNFα withdrawal24. About 80% of patients respond to a combined 
approach of steroids and biologics withdrawal26. The use of another anti-TNFα agent may result in 
recurrence of psoriasis in majority of cases (52%)25. Ustekinumab has been used in the treatment 
of CD28 and psoriasis29. There have been rare reports of paradoxical worsening of psoriasis with 
ustekinumab but not known to cause drug-induced psoriasis21. Ustekinumab is potentially an 
attractive option for treatment of refractory anti-TNFα induced psoriasis25 requiring withdrawal of 
primary drug. Methotrexate has been used but does not appear to be  effective in all cases26. It is a 
useful option to have in selected cases. (Table 3) 
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Table 3- Dermatological adverse effects with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Psoriasis 
Relatively Common 
(1.5% - 5% of patients on anti-TNFs) 
 • Clinical diagnosis 
• Histology of skin lesions 
• Establish temporal relationship between 
initiation of biologic therapy and 
development of psoriasis 
1. Specialist involvement from dermatology 
2. In mild cases: topical steroid therapy  
3. In severe cases: stop drug and consider alternatives 
such as Methotrexate 
4. Ustekinumab for managing both conditions is a 
viable alternative 
Psoriasiform lesions 
Common 
 • Clinical Diagnosis 
• Consider skin infections causing the rash 
1. Consider stopping drug in severe cases. 
2. Responds well to cessation of drug therapy 
3. Treat skin infection as appropriate 
Erythema Nodosum 
Granuloma Annulare 
Interstitial Granulomatous Dermatitis 
Very rare 
 • Clinical Diagnosis 
 
1. No clear evidence on management as these 
conditions are rare 
2. Specialist dermatology involvement is advised 
3. Usually not necessary to withhold or stop drug 
4. Clinician decision based on risk: benefit assessment 
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Autoimmune-like disorders 
Autoimmune-like disorders/syndromes are a group of conditions observed in patients on anti-TNF 
therapy. This was first described in initial studies of infliximab in patients with rheumatoid arthritis30. 
These disorders include a variety of conditions such as positive antibodies e.g. –anti-nuclear 
antibodies, anti-double stranded DNA antibodies (dsDNA) (commonly IgM type), on immunological 
testing, various systemic or organ-specific autoimmune diseases as documented in the BIOGEAS 
registry, drug-induced systemic lupus erythematosus (DIL) called lupus-like syndrome, vasculitis, 
antiphospholipid syndrome, sarcoidosis, interstitial lung disease, optical neuritis & inflammatory 
ocular disease, multiple sclerosis (MS)-like central nervous system (CNS) demyelination and 
peripheral neuropathies31.  
William et al described anti-TNFα induced lupus (ATIL) based on the severity of symptoms displayed 
and suggested that ATIL is a distinct syndrome in itself32 and are likely to be different from drug 
induced lupus. In a pooled analysis across various diseases, studies which included patients with 
IBD showed that whilst ANA positivity was very common after anti-TNF therapy (40%-56%), 
asymptomatic anti-nuclear antibodies or anti-double stranded DNA antibodies require observation 
but not discontinuation of anti-TNF. The full range of symptoms of ATIL was seen in only about <1% 
of patients32. Most patients with full blown ATIL had fever, rash, arthritis and haematological 
abnormalities.  
A large case series was reported by Costa et al comparing drug-induced lupus secondary to anti-
TNF and classic drug-induced lupus33. Both groups had similar systemic features and symptoms 
but there were some features that distinguished one group from the other. 72% of patients with anti-
TNF drug-induced lupus had cutaneous manifestations compared to about 25% in classic drug-
induced lupus group. Classic drug-induced lupus was not usually associated with antibodies to        
dsDNA and extractable nuclear antigen (ENA) or with complement consumption. 90% of anti-TNFα 
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drug-induced lupus patients were positive for anti-dsDNA antibodies and >50% had anti-extractable 
nuclear antigen antibodies and decreased serum complement levels33. 
 
Management  
The management of autoimmune-like disorders/syndromes secondary to anti-TNF therapy requires 
a customised therapeutic approach according to severity of the induced autoimmune disease. ATIL 
should be considered a distinct condition and managed accordingly. There are features which could 
help distinguish this. The incidence/prevalence of dsDNA antibodies and hypocomplementaemia is 
greater in ATIL, whilst anti-histone antibodies, the hallmark of classic drug-induced lupus, are less 
commonly found32.  
In patients with a positive ANA, it is not in itself an indication for discontinuation of therapy. In the 
presence of mild features, cessation of therapy is probably sufficient. However, it can be continued 
in patients with isolated cutaneous lesions or immunological alterations in whom biologics are 
thought to be essential to treat underlying disease, with closer follow-up. In patients with involvement 
of internal organs (kidney, lungs, nervous system), cessation of therapy is mandatory with addition 
of corticosteroids and/or immunosuppressive agents30,33. After discontinuation of the incriminating 
anti-TNF the prognosis is generally very favourable. The presence of diagnosed SLE is a 
contraindication to anti-TNF exposure. 
Cardiac effects 
It was reported that worsening cardiac failure was a possible adverse event in a randomised 
controlled trial investigating the use of anti-TNF therapy in cardiac failure34. Majority of patients 
enrolled were New York Heart Association III (NYHA) at baseline and the group receiving high dose 
infliximab (10 mg/kg) were adversely affected with an increased likelihood of hospitalization, high 
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frequency of worsening heart failure, with the risk of adverse clinical events persisting for up to five 
months after cessation of therapy34. The exact mechanism of heart failure with anti-TNFα use 
remains unclear.  
There have been case reports of second degree and complete heart block after infliximab therapy 
but are rare35. This is more likely to happen in rheumatological conditions as there may be underlying 
cardiac involvement. A single blind prospective study which included rheumatological conditions 
concluded that new-onset cardiac arrhythmias, particularly ventricular tachyarrhythmia, developed 
during infliximab infusion, but their incidence did not achieve statistical significance36. Acute 
coronary syndrome following infusion has been reported but this too is very rare37. The rarer cardiac 
effects are based on reports with a very small number of patients, mostly from the rheumatology 
cohort who are at higher risk of having cardiac disorders.  
Management 
Current guidance recommends that use of anti-TNF therapy is best avoided in those with NYHA 
III/IV heart failure38. All patients who develop heart failure while on an anti-TNF agent should 
discontinue therapy, conventional medication for treatment of heart failure started and specialty 
advice sought. An alternate class of agent should be considered for the primary disease process. It 
is still unclear whether infliximab can be used safely in patients with asymptomatic left ventricular 
dysfunction or mild symptoms of heart failure (NYHA class I/II) 38. For patients commencing            
anti-TNF therapy who have specific cardiac risk factors such as hypertension, valve disorders or 
ischemic heart disease, our recommendation is that clinicians should get a baseline 
electrocardiogram to record QT interval among other features and clinically assess the patient for 
any features of pre-existing heart failure that may preclude therapy. Not all studies have 
substantiated an association of anti-TNF therapy with heart failure and this is rare in patients with 
IBD. 
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Anti – TNF : Anti-Tumour Necrosis Factor; NYHA- New York Heart Association  
 
 
Table 4- Cardiac adverse effects with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Cardiac Failure  • Clinical diagnosis 
• Objective assessments with 
investigations 
 
1. Avoid anti-TNFs in NYHA III and IV heart failure  
2. If drug precipitates heart failure: stop the drug 
3. Treat for heart failure with diuretics and early 
specialist involvement 
4. Switch to another class of drugs 
Second and third-degree Heart Block 
More commonly seen in the treatment of 
rheumatological conditions; less so with IBD 
 • 12 Lead ECG 
• Cardiac monitoring 
 
1. Monitor patients for features of decompensation 
2. Specialist involvement for further management  
3. Stop drug and switch to another class  
Arrhythmias 
More commonly seen in the treatment of 
rheumatological conditions; less so with IBD 
 
 • 12 Lead ECG 
• Cardiac monitoring 
 
1. Usually transient and does not need any specific 
management 
2. If transient episodes are self-limiting: consider 
continuing drug 
3. If persistent: seek specialist cardiology opinion 
19 
 
Neurological effects 
Demyelination 
Demyelination has been recognised as a complication of anti-TNF therapy.  A review of FDA 
adverse event recording system showed that among 772 reports of neurological complications, 18% 
of patients had IBD. About 36% of patients had received infliximab and peripheral neuropathy was 
the most commonly reported event39. Demyelination can occur in central or peripheral nervous 
systems40. It is unclear as to whether the relationship is truly causal, or whether anti-TNF triggers 
an existing tendency for demyelination.  
Management 
The patients who have a family history of demyelination disorders may be at higher risk and this 
should be considered before the therapeutic agent is chosen41. It is standard guidance to avoid anti-
TNF therapy in patients with concomitant multiple sclerosis or history of optic neuritis. In patients 
who develop neurological deterioration and suspected demyelination during therapy, treatment with 
biologic agent should be discontinued41 and specialist neurology opinion should be sought. The 
clear relationship between demyelinating events and anti-TNF can be difficult to establish as IBD 
may also be associated with demyelination. Treatment with corticosteroids, IVIG and 
plasmapheresis are rarely necessary.  (Table 5) 
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Table 5- Neurological reactions with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Demyelination 
Known to worsen 
demyelination in patients with 
multiple sclerosis 
 
 
 
• Clinical diagnosis 
• Nerve Conduction Studies 
• MRI 
 
1. Stop drug and consider 
alternatives 
2. Seek specialist Neurology 
involvement  
3. Consider pulse therapy with 
high dose methylprednisolone  
4. Consider IV Immunoglobulin 
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Infections and management strategies 
Biologics are strong immunosuppressive agents and can increase risk of infection depending on 
their mechanism of action. TNFα is essential for activation, differentiation and recruitment of several 
immunological cell types; it has a role in granuloma formation, maintenance of granuloma integrity42 
and host response to mycobacteria and intracellular organisms43. A recent meta-analysis found that 
anti-TNF therapy was associated with a greater infection risk than placebo in treating UC but anti-
integrin therapy was not; neither class showed an increased infection risk over placebo in CD44. 
Other studies have confirmed increased risk in both forms of IBD.  
A recent systematic review by Wheat et al concluded that at present there is no evidence of a higher 
odds of serious infection from the newly available biologic therapies such as vedolizumab and 
ustekinumab compared to anti-TNFs45. Feagan et al report that infections in patients exposed to 
ustekinumab for CD is no higher than placebo in UNITI trials46 and Wils et al reported 1 serious 
pulmonary infection in a cohort of 122 ustekinumab patients, followed up over 2 years47. Bye et al 
reported an increased risk of Clostridium difficile infection with vedolizumab therapy but concomitant 
steroid and narcotic analgesics were identified as risk factors48.    
Bacterial infections 
Patients receiving anti-TNF therapy have been reported to acquire both common and uncommon 
bacterial infections. Common sites for infection include upper and lower respiratory tracts, skin and 
subcutaneous tissue, urinary tract and GI tract49.  
Management 
Common infections are treated with oral antibiotics as per local guidelines. A pragmatic approach 
would be to have a lower threshold to start treatment and switch to intravenous drugs in the presence 
of systemic symptoms. In severe sepsis requiring prolonged antimicrobial treatment, anti-TNF 
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therapy may have to be withheld. Restarting therapy can be considered once patients are afebrile, 
white cell counts within normal range and relevant imaging (CT, MRI pelvis) show no evidence of 
infective source. (Table 6) 
Uncommon infections 
Several non-mycobacterial intracellular infections, including listeriosis caused by Listeria 
monocytogenes and legionnaires’ disease most often caused by Legionella pneumophilia , have 
been associated with anti-TNF therapy50.  Listeria sepsis and meningitis has been described in 
patients receiving anti-TNF drugs51 and in 2011, the FDA added a boxed warning about the risk of 
listeriosis and legionnaires’ disease for the entire class of TNFα inhibitors52. There are a few case 
reports of listeriosis complicating anti-TNF therapy. Listeriosis carries significant mortality, therefore 
requiring prompt diagnosis and aggressive treatment. The risk appears to be higher during the first 
year of therapy53. Anti-TNF should be discontinued till the patient recovers from listeriosis.  
Management 
Suspicion of infection requires confirmatory testing and treatment using standard antibiotic regimes 
depending on pathogen isolated. Listeriosis is more likely to be seen in patients consuming mould-
ripened cheese regardless of whether it is from pasteurised or unpasteurised milk and also from 
cold smoked gravad fish54. In one study from USA, unpasteurised milk and dairy products were 
noted to significantly increase the risk of infections caused by E-coli, Salmonella and 
Campylobacter55. In view of this overall increased risk of infections, it is safer for patients to avoid 
consumption of unpasteurised milk whilst on anti-TNF drugs.  
Mycobacteria and tuberculosis  
Tuberculosis (TB) caused by mycobacterium bacilli is a serious infection which carries significant 
morbidity. TNFα is necessary for a Th1-based cell-mediated immune response important in 
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activating macrophages to kill intracellular mycobacteria, and limit spread by formation of 
granulomas56,57. The majority of exposed immunocompetent hosts have latent TB (LTB) which can 
subsequently lead to reactivation of infection if there is compromise to the immune system, such as 
initiation of anti-TNF drugs58. It is therefore critical to identify and treat LTB prior to starting anti-TNF 
therapy58. 
An association between anti-TNF therapy and development of TB was noted when the FDA 
MedWatch spontaneous reporting system demonstrated 70 TB cases in a median of 12 weeks after 
initial infliximab exposure, in 200159-68. Both extra-pulmonary and disseminated TB are more 
common in patients treated with anti-TNF therapy, compared with immunocompetent patients59-60. 
It has been hypothesised that the early occurrence of TB after infliximab may suggest reactivation 
of LTB rather than a de novo infection60. Due to the high risk of reactivation, screening for TB is 
recommended prior to starting anti-TNFα.  
The diagnosis of LTB can be difficult and should include a combination of detailed history and 
supportive investigations. At present, IGRA (interferon gamma release assay) and TST (tuberculin 
skin test) are commonly used in most centres. In a study by Mariette et al which looked at how 
effective the available tests are, it was noted that when one of the IGRA tests replaced TST, it 
influenced the decision made by physicians, leading to 28% fewer patients receiving anti-TB (ATB) 
prophylaxis61. This is likely because IGRA tests are more specific. As per this study, IGRA does not 
appear to be affected by corticosteroid or immunosuppressant therapy61. However, this may not 
always be the case as shown in an ex vivo study in which corticosteroids and infliximab reduced the 
performance of IGRA62. At present, IGRA is possibly more reliable than the other options available.  
TST is less specific and can be less frequently positive due to corticosteroid or immunosuppressant 
therapy and this should be borne in mind. Based on their findings, Mariette et al proposed the an 
algorithm for assessing patient, which is now generally applied prior to starting anti-TNFα therapy61. 
All patients should undergo appropriate history +/- chest x-ray. For those with a positive history or 
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x-ray, treat with ATB prophylaxis. For those with negative history, check with IGRA test (authors 
recommend GOLD, followed by T-SPOT if indeterminate). Those with negative results require no 
further screening. Those with positive results require ATB prophylaxis. Patients with indeterminate 
GOLD and T-SPOT test should undergo TST testing. Negative results require no further action, but 
a positive TST should be treated with prophylaxis61.  
In patients who have a positive TST and negative IGRA, the degree of clinical suspicion should 
guide management, based on history and chest x-ray with a very low threshold to treat the patient. 
Generally, performing both TST and IGRA is not recommended. An initial indeterminate borderline 
IGRA can be followed up with TST and if the latter is positive the patient should be treated. The 
CDC recommend testing with either IGRA or TST, but a combination of both may be appropriate 
where clinical suspicion of LTB is high, or risk of subsequent LTB reactivation may result in a poorer 
outcome (such as those on immunosuppressants)63.  
Management 
Guidelines by European Crohn’s and Colitis organisation (ECCO)26 and British Thoracic Society 
(BTS)58 on screening and management of TB are similar in principle, suggesting treatment of LTB 
prior to initiation of anti-TNF therapy with a complete therapeutic regimen. If there is clinical 
suspicion +/- radiographic changes suggestive of TB, patients should be referred for treatment of 
LTB58. Other patients should undergo LTB screening tests. The optimal screening strategy for these 
patients is still debatable.  
After diagnosis of latent TB in a patient with IBD, appropriate treatment should be administered for 
at least 3 weeks prior to commencement of anti-TNF therapy64,65 ; however if treatment with anti-
TNF therapy is considered very urgent simultaneous treatment for latent TB and IBD may be 
considered. Alternative therapies such as vedolizumab or ustekinumab may also be considered for 
UC or CD. Short latent TB therapies are increasingly considered such as rifampicin for 4 months or 
isoniazid plus rifampicin for 3 months as adherence to 9 months of daily isoniazid poses 
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challenges66,67. Exposure to active TB during anti-TNF therapy should lead to prompt re-evaluation 
for latent or active TB. In case of active TB, anti-TNF should be discontinued and active TB treated. 
If absolutely necessary, anti-TNF may be resumed after at least 2 months of anti-TB therapy with 
satisfactory response, though it may sometimes be resumed earlier if absolutely necessary. 
Increasingly other monoclonal antibodies such as ustekinumab or vedolizumab are being 
considered. Annual re-testing for LTB in patients on anti-TNF therapy depends on risk factors for 
exposure to TB and desirable in geographical areas with endemic TB. (Table 6) 
 
26 
 
WCC-white cell count 
 
 
Table 6- Bacterial infections with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Common bacterial infections    
Respiratory Tract 
Urinary Tract 
Gastrointestinal 
Cellulitis 
 
 
• Clinical diagnosis 
• Relevant investigations depending on symptoms 
 
1. Appropriate antibiotics based on site of 
infection 
2. Consider early therapy 
3. If any signs of sepsis: stop drug 
4. Restart biologics when good evidence of 
resolved infection. (WCC, imaging) 
Serious Bacterial Infections:    
Listeriosis 
Legionnaires’ disease 
Septic Arthritis 
Septicemia 
 
 
• Serology 
• CT/MRI of brain 
• Lumbar puncture if meningitis suspected 
 
1. Appropriate antibiotics based on sensitivity 
2. Seek specialist microbiology advice 
 
Tuberculosis (TB):    
Latent TB Re-Activation  • Risk assessment based on initial screening with 
Quantiferon or T-Spot Testing 
• Thorough history and risk factor assessment 
• Chest X-Ray 
 
1. If positive or indeterminate: involve 
specialists 
2. Treat as per ECCO guidelines and British 
Thoracic Society Guidelines 
3. Risk: Benefit analysis by clinician 
4. Consider alternative therapy i.e. 
vedolizumab or ustekinumab 
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Viral infections 
A majority of human viral infections are self-limiting but some are capable of causing chronic 
infection [e.g. human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus 
(HCV)]. There are viruses linked to malignancy, such as Epstein-Barr virus (EBV) and human 
papilloma virus (HPV). EBV will be discussed in more detail in ‘malignancy’ section of this text. 
Varicella (VZV) and Shingles 
This can present with severe or disseminated disease if contracted while on anti-TNF therapy68. In 
one study, the prevalence of prior varicella zoster virus (VZV) infection among IBD patients was 
greater than 90%69 and it was not noted that a significant number had a VZV IgG negative status. It 
is known that patients with IBD are at a higher risk of VZV infection and more so when on 
immunosuppressive therapy7071.   
Herpes zoster or shingles is caused by reactivation of VZV. The incidence of shingles is again 
increased in patients with IBD, the elderly population at particular risk. In a study looking at herpes 
zoster in IBD, it was seen that patients with CD were at higher risk; age >45 years, treatment with 
corticosteroids for >2 weeks, thiopurine therapy were associated with increased risk of infection72. 
Long et al reported similar findings and also noted that patients on anti-TNF therapy for IBD are at 
higher risk of herpes zoster with an odds ratio of 1.81 (95% CI: 1.48-2.21)73.  
Management 
Immunocompromised patients exposed to VZV should be treated with VZV immunoglobulin74. 
Patients who contract VZV or shingles during a period of immunosuppression require antiviral 
therapy. If oral therapy is appropriate, valganciclovir should be considered as this provides higher 
oral bioavailability than aciclovir75. (Table 7) 
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Prevention of infection is possible due to availability of effective vaccines. It is recommended that 
all patients are screened for evidence of past infection prior to starting biologics or 
immunosuppressives including steroids. ECCO suggest that in seronegative patients two-dose 
course of varicella vaccine should be given at least 3 weeks prior to commencement of therapy65. If 
subsequent immunisation is necessary, it can be administered after a 3–6 month cessation of all 
immunosuppressives as both the VZV and shingles vaccines are live vaccines75, although there is 
emerging evidence that administration of live zoster vaccine to patients already on anti-TNF therapy 
did not result in disease and there was expected immune response to the vaccine73.   
Hepatitis B 
TNFα and interferon (IFN)γ are released by cytotoxic T lymphocytes on antigen recognition of the 
hepatitis B virus (HBV), activating two viricidal pathways, plus antigen non-specific T cells & 
macrophages76. Reactivation of HBV may occur during anti-TNF therapy, or on subsequent 
withdrawal (secondary to immune reconstitution). Reactivation of chronic HBV carriers (hepatitis B 
surface antigen (HBsAg) positive, undetectable HBV DNA, normal LFTs) after anti-TNF therapy has 
been reported77. Patients who have had HBsAg seroconversion following exposure to HBV [HBsAg 
negative, anti-HBc (core antibody) positive and anti-HBsAg antibody positive] have been 
successfully treated with anti-TNF therapy without HBV reactivation during follow up78. Chronic 
active HBV patients already successfully controlled with antiviral therapy prior to introduction of   
anti-TNF show no deterioration in the viral load or liver enzymes79,80. A comprehensive review by 
Pattullo81 looked at incidence & prevalence of HBV reactivation in IBD when treated with 
immunosuppressants without HBV prophylaxis; risk stratification of patients was also done based 
on type of biologic therapy81. The incidence of immunosuppression related HBV reactivation was 
noted to be about 36% in HBsAg positive patients. The overall prevalence of HBV in IBD ranged 
from 0.6-17% for HBsAg positive patients, and 1.6-42% for HBsAg negative/anti-HBc positive 
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patients. The risk estimate of HBV reactivation was reported to be moderate (1-10%) with anti-
TNF81.  
Management  
All patients should be screened prior to initiation of therapy, although which patients should receive 
antiviral therapy remains unclear. Screening should be carried out checking for hepatitis B surface 
antigen, antibody to surface antigen & anti HB core antibody levels and if HBsAg or anti-HBc is 
positive, DNA quantification should be done65. Chronic HBV carriers and those with HbsAg 
seroconversion should be considered for antiviral therapy and hepatology involvement. It is 
recommended that patients who are due to start biologics (moderate risk) are given anti-viral 
prophylaxis if they are HBsAg positive and continued for at least 6 months after completion of 
immunosuppressive therapy81. In case of reactivation, it is recommended that one of the antivirals 
is started and continued for at least 6 to 12 months after immunosuppressive therapy has been 
stopped. The antiviral medication of choice may depend on the patient’s individual circumstances, 
and the planned duration of immunosupression82. Entecavir and tenofovir are now preferred anti-
virals in IBD patients due to their rapid onset of action, highest anti-viral potency with low incidence 
of resistance65. Whilst lamivudine is used, this has its limitations if long term therapy is required, as 
resistance can occur in up to 30% of patients after 1 year and 70% after 5 years82. Peginterferon-
alpha-2a (IFNα) is best avoided due to the risk of myelosuppression and also risk of exacerbating 
CD65.  
Hepatitis C  
TNFα appears to be involved in the pathogenesis of HCV, with patients with higher serum TNFα 
levels less likely to respond to anti-viral therapy83. TNFα blockade may increase reactivity of 
peripheral T cells to antigen stimulation83. Biologics have an acceptable safety profile for use in 
patients with HCV and is not contraindicated in concomitant HCV infection.  However, in the 
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presence of acute HCV, anti-TNF therapy is contraindicated84. In the presence of chronic HCV, the 
decision to treat with anti-TNF depends on liver synthetic function. It is best avoided in patients who 
are Child-Pugh category B or C84. HCV patients being treated with anti-TNF therapy should have 
close monitoring of aminotransferases with consideration for discontinuation of treatment with 
continued elevations83. The guidelines from ECCO suggest cautious use of antivirals due to drug 
interactions65. Infection diagnosed whilst on anti-TNF therapy does not necessarily require cessation 
of therapy65. There is no data yet on the use of newer antivirals for HCV in the context of biologics 
use for IBD but there are no contraindications for their concurrent use. 
Management 
The ECCO guidelines are equivocal about screening for HCV prior to use of immunosuppressive 
therapy65. However, it would be prudent to screen patients who are likely to need biologics 
considering the high curative rates with newer anti-viral drugs for HCV. All patients with HCV 
infection should be discussed and managed jointly with hepatology services, especially when 
biologics are indicated for IBD. During the course of therapy, close monitoring of liver functions is 
key.  
HIV infection 
The interaction between TNFα and the human immunodeficiency virus (HIV) has been the subject 
of much scrutiny. The molecular pathway by which HIV expression is upregulated by TNFα is well 
described85,86. Despite these findings, use of anti-TNF in HIV-patients must be balanced with a 
potential increase in the risk of opportunistic infections in patients with an attenuated immune 
system.  
The evidence base for advice regarding use of biologics in patients with HIV and IBD is limited. 
Within a cohort study and several case reports, biologic therapy with infliximab in refractory IBD 
patients has been demonstrated to be effective in inducing disease remission with only a minority 
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experiencing adverse effects87-77. It is important to note that initial CD4+ count in patients included 
in these studies are > 200 cells/mL. The ECCO guidelines65 also suggest that the HIV-IBD cohort 
of patients are less predisposed to infection on highly active anti-retroviral therapy (HAART) than if 
they did not receive HAART. In this cohort, adverse effects have presented as either a pre-
disposition to infections, deranged CD4+ count or HIV viral loads.  
Abreu et al describe an HIV positive, thiopurine-intolerant patient treated with IFX for a UC-flare 
unresponsive to steroids88 who had been on ART (emtricitabine/tenofovir/efavirenz) with 
undetectable HIV viral load & CD4+ count of 357/mmc prior to infliximab therapy. Although excellent 
disease response was achieved, he was diagnosed with listeriosis and was successfully treated. 
(CD4+ count 350/mmc). Infliximab was restarted with no clinical consequences. It is likely these 
patients with IBD remain at increased risk of opportunistic infections89. 
Other examples of adverse effects of biologics in HIV are reported in the rheumatology cohort90. In 
one case series91, a patient who was not on HAART therapy was observed to have an increase in 
viral load (22,148 c/ml to 428,503 c/ml) following initiation of infliximab therapy. This required 
temporary cessation of infliximab and the rise was not observed at re-administration.  
Within the limited evidence available, it is noted that patients do benefit from adequate disease 
response with no specific HIV-related complications. Due to risk of AEs, it is recommended that 
screening for HIV is undertaken prior to treatment with biologics and patients with IBD recognised 
as HIV positive are managed by a multi-specialty team. Generally, in the absence of other infections 
treatment of HIV infected patients with anti-TNF is relatively safe. This group of patients must ideally 
be on HAART. A discussion about potential increased risk of infection, baseline blood tests including 
CD4+ count (ideally 200 cells/mL+), and HIV viral load is necessary. Close monitoring throughout 
duration of therapy is key. An Increase in HIV viral load needs discussion with specialists and 
discontinuation of biologic may become necessary. Any overt sign of infection merits hospital 
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admission to identify and treat the infection source and biologics paused. Restarting biologics should 
be discussed based on clinical aspects of each case. (Table 7) 
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Anti – TNF : Anti-Tumour Necrosis Factor ; HBV-Hepatitis B virus; HCV-Hepatitis C virus; LFTs- liver function tests; PCR- polymerase chain reaction; HAART- highly active antiretroviral therapy 
 
Table 7- Viral infections in the use of anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Varicella 
Relatively common 
 • Clinical diagnosis 
• Serology testing available 
1. Treat with varicella immunoglobulin 
2. Antimicrobial therapy with valganciclovir 
Chronic Stable HBV 
Reactivation of chronic 
infection 
 • Screening for HBV mandatory 
• Close monitoring of liver function and viral load 
 
1. Joint care with Hepatologist 
2. May require treatment with antivirals  
3. Biologics can be continued unless acute fulminant liver failure 
suspected 
Chronic Active HBV 
on antiviral therapy 
 • Screening for HBV mandatory 
• Close monitoring of liver function and viral load 
1. Continue antivirals 
2. Entecavir and tenofovir drugs of choice 
Hepatitis C  • Screening for HCV recommended prior to anti-TNF 
therapy 
• Close monitoring of LFTs and HCV RNA load in HCV 
infected patients 
 
1. Joint care with Hepatologist 
2. Continue biologic with close monitoring 
3. No contraindication for therapy 
Cytomegalovirus 
(CMV) 
 • Check serology for CMV IgM and viral PCR 
• Supported by tissue diagnosis with histology and 
immunohistochemistry 
1. Treatment with IV ganciclovir and switch to oral valganciclovir 
for total of 2-3 weeks 
2. Use foscarnet as per sensitivities 
3. If systemic CMV infection: consider stopping anti-TNF 
Human 
Immunodeficiency 
Virus  
 • Close monitoring in addition to CD4+ counts 
 
1. Continue biologics when HAART established and CD4+ counts 
are above 350 
2. Consider withholding biologic when CD4+ <200 
3. Joint care with multidisciplinary decision approach 
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Fungal infections  
Patients with IBD are known to be at an increased risk of fungal infections. This is due to multiple 
factors such as severity of disease activity, comorbidities, treatment with opioids, surgery, poor 
nutritional status, leucopenia and older age92. Another factor is immunosuppressive therapy, 
important of which are anti-TNFs.  A risk factor analysis by one recent systematic review reported 
anti-TNF therapy as the predominant factor associated with fungal infections92.  
Aspergillosis 
Aspergillosis, caused by Aspergillus fumigatus is a serious pulmonary infection which warrants 
prompt diagnosis and treatment. Attenuation of the inflammatory pathway through TNFα blockade 
alters the cytotoxic immune response to fungal infections and in aspergillosis, it is involved in 
polymorphonuclear leucocyte activation in response to infection93. The evidence is mostly from case 
reports. In 2001, a case of invasive pulmonary aspergillosis was reported in a patient with CD on 
anti-TNF therapy94. There have been other case reports since but overall, it appears to be a rare 
occurrence. This usually presents initially with a poorly productive cough and can progress to 
respiratory insufficiency; radiological changes are seen94-95. 
Management 
The definitive diagnosis is on culture of broncho-alveolar fluid. The infection is treated with prolonged 
anti-fungal therapy based on sensitivities; amphotericin B or voriconazole or caspofungin is used. 
The condition carries very poor prognosis. Concomitant tuberculous cavity needs exclusion. (Table 
8) 
Histoplasmosis  
This is another potential opportunistic infection reported in patients exposed to anti-TNF treatment.  
In a case series of ten immunocompromised subjects from an area endemic with histoplasmosis, 9 
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contracted histoplasmosis shortly after commencing infliximab infusions. Clinical presentation can 
be varied and include pulmonary, extra-pulmonary or disseminated disease symptoms which are 
non-specific96. 
Management 
Invasive fungal infections should be treated with systemic antifungals and all immunosuppressant 
medication should be reviewed. The FDA in 2008 have issued post market drug safety information 
alerting healthcare providers that invasive fungal infections and histoplasmosis in patients receiving 
anti-TNF drugs are not being swiftly recognised, resulting in possible delays to patient therapy. The 
FDA recommends the involvement of infectious diseases specialists97 in the management of such 
cases. (Table 8) 
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Table 8- Fungal infections with anti-TNF therapy 
Complication  Diagnosis Management Strategy 
Candidiasis 
Commonly 
localised 
infections but 
systemic and 
invasive infection 
can be life 
threatening 
 • Serology, culture and molecular 
studies 
 
 
 
1. Localised infections: Topical therapy 
2. Invasive infections:  
i. Stop biologic 
ii. IV Fluconazole 
iii. Seek specialist advice 
Aspergillosis 
Pulmonary 
symptoms and 
invasive infection 
 
 • Serology, culture and imaging 
 
1. Stop biologics 
2. IV Anti-fungal therapy 
        (Consider IV voriconazole) 
3. Caspofungin is another option 
4. Specialist involvement 
Histoplasmosis 
Usually pulmonary 
infection 
 
 • Serology, culture and radiology 
 
1. Stop biologic therapy 
2. Treatment with either one of: 
i. Amphotericin B initially and step-
down therapy to an azole 
preparation  
ii. Itraconazole  
Pneumocystis 
Jirovecci 
 
 • Clinical diagnosis 
• Culture, microscopic and 
molecular diagnosis 
1. Co-trimoxazole 960mg BD, if severe 
infection increases to 1.44 g BD 
2. Specialist involvement 
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Other Opportunistic infections 
Cytomegalovirus (CMV)  
CMV infection (detected by serology) could be due to reactivation of latent infection during 
immunomodulator or biologic therapy, but usually is itself mild or asymptomatic even on 
immunosuppressants. However, CMV colitis, retinitis, pneumonia or severe CMV infection during 
treatment of IBD requires further assessment75 to plan management. Nevertheless, not all cases of 
CMV infection in anti-TNF use progress to CMV disease98.  
The diagnosis of CMV disease using histopathology with immunohistochemistry is highly sensitive 
and specific. This combined with CMV viral load (CMV DNA detected by PCR in serum & tissues) 
can provide most information about disease state75. CMV viral loads of >250 copies/mg is a predictor 
for patients presenting with corticosteroid-resistant disease75. 
CMV disease manifesting as colitis is a recognised complication of IBD and should be screened for 
in those patients presenting with acute severe colitis99. Typically, patients may have had previous 
exposure to immunosuppressive therapy and experienced prolonged corticosteroid therapy or 
corticosteroid-refractory disease.  CMV can also be a cause of chronic pouchitis100. 
Management 
It is important that diagnosis is established swiftly. When considered as a differential diagnosis, 
testing for CMV viral load with PCR is recommended to look for CMV disease especially in ill patients 
with systemic manifestations. Histology and immunohistochemistry may be used to support the 
diagnosis of CMV colitis. Once diagnosed, ECCO recommend a 2-3 week course of ganciclovir 
therapy for CMV disease, and immunosuppressants are withheld75. However, a retrospective cohort 
case study of CMV-positive colitides, identified that patients with milder colitis were less likely to be 
treated, and could respond to standard immunosuppressive therapy without additional treatment for 
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CMV. CMV may be transiently reactivated and disappear without antiviral therapy. In one study it 
was noted that those with more severe disease were more likely to be treated with ganciclovir, and 
were more likely to require either rescue therapy or surgery, despite adequate treatment of CMV101. 
CMV colitis complicating UC leading to acute severe colitis can be challenging to manage. A study 
by Kopylov et al reported that the outcomes for patients with severe colitis. Patients received 
infliximab/ciclosporin with ganciclovir vs ganciclovir alone, and they had similar colectomy rates102. 
In patients who test positive for CMV whilst on anti-TNF therapy, there is a evidence that anti-TNF 
can be continued103. (Table 7) 
Pneumocystis pneumonia (PCP) or pneumocystis jirovecci pneumonia (PJP) 
This is a serious infection reported in patients after use of immunosuppressants. A large population 
based cohort study looked at risk of PJP in IBD patients104. Although there is some evidence that 
the overall hazard risk of PJP in IBD is higher than normal population, the absolute risk of PJP is 
considered to be very low (0.03% in their cohort)104. In a large case series of PJP after infliximab 
use, mean onset of symptoms reported was 21 days although majority of patients were exposed to 
concomitant immunosuppressive therapy. Over a quarter (27%) of patients died105 in these reported 
series, so early recognition and therapy is paramount. ECCO guidance recommends that patients 
on triple immunotherapy with one being a calcineurin inhibitor or anti-TNF should receive        
standard prophylaxis with Trimethoprim-sulfamethoxazole (co-trimoxazole) if tolerated. It should be 
considered in those on dual immunosuppression especially if one is a calcineurin inhibitor75 and in 
anti-TNF regimens with associated corticosteroid use75. However, pill-burden and side effects are 
to be kept in mind. Co-trimoxazole is an effective option for prophylaxis and active infection. 
Clinicians should discuss with their local microbiology and infectious disease departments. Although 
more recent studies report very low risk, clinicians have to be vigilant throughout the course of 
treatment and decision on prophylaxis has to be on a case-by-case basis. (Table 8) 
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Infection prevention and vaccination recommendations 
The main focus of the article is on management of adverse effects and our stress on prevention 
though very important, is limited as these have been extensively addressed in ECCO guidelines. 
ECCO guidance recommends that prior to immunosuppression a detailed history and examination 
including prior bacterial, viral and fungal infections, particularly herpes, VZV, TB exposure, 
prolonged travel/stay or plans to travel to TB endemic or tropical areas and completion of childhood 
vaccination programmes. Further advice should include cervical smear screening for women, food 
hygiene and avoidance of raw and unpasteurised foods. Education on safe use and preparation of 
dairy & meat products can benefit patients at risk of Listeria infection whilst on anti-TNFα therapy. 
Live attenuated vaccines must be avoided on immunomodulator or anti-TNF therapy and ideally 
patients should receive annual inactivated influenza vaccine and pneumococcal vaccine as 
required. Prior to the onset of immunosuppression, consider vaccination with any outstanding 
routine vaccines plus HBV, VZV (if seronegative and no clinical history) and HPV75. If patients 
require live vaccines during therapy, the risk: benefit assessment of vaccination should be 
undertaken. Patients are usually immunocompetent within 3-12 months106 after cessation of therapy. 
Corticosteroid therapy alone is not considered to cause significant immunocompromise unless high 
doses (20mg or higher) have been used continuously for more than two weeks106. 
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Malignancy 
Malignancies thought to be linked to immunosuppressive agents and anti-TNF use include solid 
organ malignancies, non-melanoma skin cancer (NMSC), melanoma, lymphoproliferative 
malignancies, and those with viral association such as EBV-related lymphomas and HPV-related 
cervical cancers or dysplasia. However, difficulty remains in establishing a cause-effect relationship.  
A possible association between anti-TNF use and malignancy first arose from post-marketing 
reports to the FDA. There were 26 cases of lymphoma reported in patients with rheumatoid arthritis 
or CD disease treated with etanercept or infliximab107.  Further studies demonstrated an increased 
risk for solid organ and NMSC in patients treated with anti-TNF and further immunosuppressive 
therapies108. Many IBD patients are either on multidrug regimes or have had past exposure to 
thiopurines (or other immunosuppressants) prior to anti-TNF usage. 
Historically most trial data is from the rheumatology population.  A meta-analysis derived from nine 
clinical trials of patients receiving anti-TNF treatment or placebo identified a number needed to harm 
of 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months109. 
The malignancy rates were significantly more common in those treated with higher doses (≥6mg/kg 
of infliximab every 8 weeks or 40mg of adalimumab alternate weeks)109. A more recent meta-
analysis of 74 randomised controlled trials concerning adalimumab and infliximab showed no overall 
relative risk (RR) increase on short term follow up for malignancy with the exception of NMSC which 
had a RR of 2.02 (95% CI 1.11-3.95)110.  A 6-year follow up study from the national Danish registers 
only identified three solid organ malignancies and one case of melanoma, with total follow up ranging 
from 0.1-72.1 months111. The Crohn’s therapy, resource, evaluation and assessment tool (TREAT) 
registry is collecting prospective data on large number of CD patients to evaluate the long-term 
safety of CD therapies. Data published from the registry in 2006 showed mortality rates to be similar 
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between infliximab and non-infliximab patient groups after a short period of follow up (mean follow 
up 1.9 years)112. Subsequent data from the registry published in 2014 (with follow up of up to 7.6 
years) has shown that none of immunosuppressants, infliximab or combination therapy to be an 
independent risk factor for malignancy113. However, the follow-up period remains short and future 
analysis of the registry is likely to provide further evidence. 
The CESAME Study Group114 assessed the impact of thiopurine use on development of NMSC–
comprised of basal cell carcinoma, squamous cell carcinoma and lymphoproliferative disorders 
(increased risk found in the thiopurine group). Although a large number of patients were included, 
the risk of malignancy secondary to biologics could not be assessed due to relatively small number 
of patients on these drugs115. A study by Long et al published in 2010 assessed risk of malignancy 
and concluded that IBD in itself increased risk of NMSC (incidence rate ratio IRR 1.64 95% CI 1.51-
1.78) and a nested case-control model showed an increased risk because of recent biologic use 
among patients with CD (adjusted OR 2.07, 95% CI 1.28–3.33)116; patients on combination therapy 
had the highest OR compared to medication-free patients (OR 5.85 95%CI 3.2-10.8)116. Another 
study in 2012 reported that patients were at higher risk of melanoma when exposed to biologics and 
NMSCs were mainly related to thiopurine therapy117. The most recent French national cohort study 
showed an increased risk of lymphoma in treatment exposed patients. When compared with 
unexposed patients, the risk of lymphoma was higher among those exposed to thiopurine 
monotherapy (aHR, 2.60; 95% CI, 1.96-3.44; P <0.001), anti-TNF monotherapy (aHR, 2.41; 95% 
CI, 1.60-3.64; P < 0.001), or combination therapy (aHR, 6.11; 95% CI, 3.46-10.8; P < 0.001)118. 
There remains concern about cases of hepatosplenic T-cell lymphoma (HSTCL) (a rare and 
aggressive form of non-Hodgkin’s lymphoma affecting predominantly young men) occurring 
following infliximab, adalimumab or thiopurine use. In a study published by Thai et al, they reported 
22 cases of HSTCL in IBD and most were associated with thiopurine therapy either as monotherapy 
or in combination with anti-TNF. Whilst a link is recognised, quantifying this risk to individual patients 
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on current evidence is difficult119.They also concluded that despite the risk, benefits of treatment far 
outweighed the risks120.  
Secondly, observational studies have noted a potential predisposition to development of EBV 
related lymphoproliferative disorders in IBD patients, in particular those treated with thiopurines and 
anti-TNFα agents75. Patients with EBV are predisposed to post-transplant lymphoproliferative 
disorders (PTLD), where T-cell immune surveillance is impaired75.  EBV related lymphomas may 
present in the gut, rather than nodal sites. Screening for EBV should ideally be considered, however 
there is no current vaccination for EBV naïve patients. In those developing EBV on therapy, 
treatment with antiviral medication and withdrawal of therapy should be considered75. IBD itself does 
not appear to increase risk of lymphoma diagnosis121. However use of a thiopurine for IBD or 
combination therapy with an anti-TNFα may increase risk121. Establishing any isolated effect of anti-
TNFα on lymphoma development is challenging. In a meta-analysis looking at lymphoma rates in 
CD patients treated with anti-TNFα, two thirds of all patients were also receiving immunomodulator 
therapies122 ; anti-TNFα treated patients appeared to have an increased risk of lymphoma (SIR 3.23 
95% CI 1.5-6.9) compared to the expected population rate122. The SIR was also increased when 
compared to previously studied patients on immunomodulator therapy alone (1.7 95% CI 0.5-7.1), 
however this did not reach statistical significance122. There were too few patients treated with 
isolated anti-TNF therapy to determine the individual risk of anti-TNF usage on lymphoma 
development122. 
Management principles in malignancy 
The association between various malignancies and anti-TNF treatment remains unclear, but it is 
important that patients’ history of previous or pre-existing cancer is carefully documented prior to 
initiation of biologic treatment. The use of biologics as monotherapy can be considered in patients 
with previous history of cancer. Axelrad et al noted that at 5 years after prior cancer diagnosis no 
significant difference in cancer free survival could be demonstrated between IBD treatment with anti-
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TNF monotherapy, immunosuppressant monotherapy, anti-TNF combined with thiopurine therapy, 
though numerically anti-TNF monotherapy had the least cancer recurrence123. In a meta-analysis of 
16 studies of immune mediated diseases, including 8 studies involving IBD patients, similar rates of 
cancer recurrence were observed among individuals affected by previous cancer who received no 
immunosuppressives, anti-TNF monotherapy, immunosuppressant therapy or combination 
therapies124. Therefore, in patients with a history of cancer, recent or past, effective therapy for IBD 
can be used after consideration of risks & benefits and discussion with oncologists. ECCO guidelines 
also provide advice on managing IBD patients with previous history of malignancy125. Generally, 
among biologics, monotherapy anti-TNFα, vedolizumab or ustekinumab may all be used, but often 
thiopurines are avoided.  
Table 9- Malignancies with anti-TNF therapy 
Complication Causative 
drug/s 
Diagnosis Management Strategy 
Melanoma 
 
Anti-TNF  
 
• Clinical diagnosis 
• Skin biopsy 
 
1. Stop drug 
2. Consider alternatives like 
Methotrexate or vedolizumab 
3. Dermatology involvement  
Non-melanoma skin 
cancer 
 
Dual Anti-TNF  
+ thiopurine 
therapy  
 
• Clinical diagnosis 
• Skin biopsy 
 
1. Stop drug 
2. Consider alternatives like 
Methotrexate or vedolizumab 
3. Dermatology involvement  
Lymphoma 
• HSTCL 
• PTLD 
Dual Anti-TNF  
+ thiopurine 
therapy  
• Cross sectional 
imaging 
• Tissue Biopsy  
 
1. Stop drug 
2. Consider switching drug class 
Other malignancies: 
Leukoencephalopathy 
 
Dual Anti-TNF  
+ thiopurine 
therapy  
• Clinical diagnosis 
• Imaging 
• Tissue Biopsy  
1. Stop the drug 
2. Consider switching drug class 
3. Relevant Specialist involvement 
Anti – TNF : Anti-Tumour Necrosis Factor ; HSTCL: Hepatosplenic T-cell Lymphoma; PTLD: Post-transplant lymphoproliferative disorder 
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CONCLUSION 
The use of biologics is now standard therapy for IBD used either as monotherapy or in combination 
with immunomodulators. A review of safety data of currently used biologics show cumulative 
evidence for anti-TNFα as they have been used for longer duration. In summary, acute infusion 
reactions are common with anti-TNF, neutropenia is a worrying AE and may require temporary 
cessation of therapy. Infections are significantly higher with anti-TNF which include common and 
uncommon bacterial infections, mycobacterial infections (in particular TB), viral and fungal infections 
and opportunistic pathogens. Diagnostic and management strategies are outlined in separate 
tables.  
Anti-TNF therapy causes a wide range of dermatological presentations. It is important to differentiate 
drug induced psoriasis from psoriasiform rash. Treatment may range from topical therapy to anti-
TNFα withdrawal. Ustekinumab may be useful in these cases. 
Malignancies thought to be linked to anti-TNF use include solid organ malignancies, NMSC, 
melanoma, lymphoproliferative malignancies, and those with a viral association. However, difficulty 
remains in attributing a causal relationship particularly given the confounding of thiopurine use. The 
link between HSTCL is recognised but currently not quantified due to scarcity of data. IBD increases 
risk for NMSC, with the risk further increased for in combination therapy. The risk of lymphoma is 
increased with combination therapy with thiopurines including EBV related lymphoma but it is to be 
noted that results from the TREAT registry suggest that none of the immunosuppressants, infliximab 
or combination therapy are an independent risk factor for malignancy. However, the follow up 
duration remains short. Biologics can be used in patients with prior history of cancer after careful 
discussion about risks and benefits with oncologists. 
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Finally, although these therapies are often very effective, they present unique challenges.  It is likely 
that in the future biologics will be used in a wider cohort of patients earlier in their disease journey, 
and therefore prompt recognition of adverse events secondary to drugs is important. Further 
reporting of rarer AEs and prompt recording of common AEs in registries will help assess risk more 
accurately. This information should help clinicians inform their patients of risks associated with each 
therapy and will lead to more informed decision making, thus improving patient care. 
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